A new vaccine for yellow fever that is safe for everyone.
Official title: A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
Funded at Najit Technologies, INC. · NIH-10654651 · Data updated 2026-11-12
This study is testing a new yellow fever vaccine called HydroVax-YFV to see if it's safe and effective for people who can't get the usual vaccine, like infants, pregnant women, and older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Najit Technologies, INC. NIH-funded |
| Lab location | 1 site (Beaverton, UNITED STATES) |
| Project start | July 1, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $825,048 |
| NIH project number | 5U44AI145791-04 |
| Project ID | NIH-10654651 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are unable to receive the live yellow fever vaccine due to age, pregnancy, breastfeeding, or egg allergies.
✕Less likely to help
Patients who are healthy adults without contraindications to the current yellow fever vaccine may not benefit from this research.
What this research studies
This research investigates a novel inactivated yellow fever vaccine, HydroVax-YFV, designed to be safe for vulnerable populations who cannot receive the current live attenuated vaccine. The study aims to evaluate the safety and efficacy of this new vaccine in a randomized clinical trial format. Participants will be monitored for any adverse effects and immune responses to ensure the vaccine's safety profile. The goal is to provide a viable vaccination option for individuals at risk, including infants, pregnant women, and the elderly.
Why it matters
Potential benefit: If successful, this research could provide a safe vaccination option against yellow fever for individuals who are currently at risk due to contraindications with the existing vaccine.
How similar studies have gone: While the current approach is novel, previous research has shown that inactivated vaccines can be effective alternatives to live attenuated vaccines in other contexts.
Where this research is happening
-
Najit Technologies, INC.
Beaverton, United States Active
Researchers
- Principal investigator: Amanna, Ian James — Najit Technologies, INC.
- Study coordinator: Amanna, Ian James
Related research
Other NIH-funded projects on the same topics.
-
Broad antiviral drugs that target coronaviruses and other viruses
A research program aims to identify small molecules that can block multiple viruses, focusing first on coronaviruses, to help create drugs that can treat future outbreaks.
-
Finding broadly protective antibodies against Crimean-Congo Hemorrhagic Fever
Researchers will study blood from people who survived CCHF to find human antibodies that protect against multiple virus variants, with early tests in animal models to check their breadth.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
A New Model for Valley Fever: Studying Coccidioides Infection with Volatile Clues in Wax Moths
Researchers are testing a new, cheaper model using wax moths to study Valley Fever caused by Coccidioides, with the goal of understanding how the infection behaves and how it could be diagnosed or treated.
-
Halogen-modified nucleoside analogs to fight yellow fever virus
Aims to develop new oral medicines that could prevent or treat yellow fever by using specially modified building blocks that stop the virus from growing.
-
Understanding Guanarito virus and building countermeasures for Venezuelan hemorrhagic fever
This project studies how Guanarito virus causes disease and aims to develop vaccines or treatments to protect people in areas where Venezuelan hemorrhagic fever occurs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.